When Dr. Xin Du and colleagues at Xiamen Humanity Hospital began reviewing the cardiac records of 163 patients in early 2022, they uncovered a hidden crisis lurking inside a common heart condition. Their findings, published in BMC Cardiovascular Disorders, reveal that nearly half of patients with heart failure with preserved ejection fraction—a condition where the heart muscle contracts normally but fills inadequately—also have right ventricular dysfunction, a complication that had largely gone unrecognized.
The study found that 41.7 percent of HFpEF patients showed signs of right ventricular impairment, a number that surprised even the researchers. The right ventricle, which pumps blood to the lungs, can struggle when the left side of the heart stiffens and pressures back up through the circulatory system. Until now, there was no reliable way to identify which patients were affected.
What makes this research valuable isn't just the prevalence data—it's what the team discovered about detection. By combining six echocardiographic measurements with a blood marker called NT-proBNP, they built a predictive model with remarkable accuracy. The combined approach achieved a diagnostic score of 0.989 on the receiver operating characteristic curve, meaning it correctly identified dysfunction in nearly every case.
Among individual measures, right ventricular free wall strain showed the strongest predictive power. The other five parameters—TAPSE, systolic pulmonary artery pressure, the ratio of early mitral inflow to annular velocity, left atrial volume index, and fractional area change—worked together to fill in the gaps, creating a comprehensive picture of heart function that no single test could achieve alone.
The researchers say the implications are straightforward: if hospitals routinely use this multiparametric approach alongside standard NT-proBNP testing, they can catch right ventricular dysfunction years before it causes serious problems. Earlier detection means earlier treatment, and earlier treatment means better outcomes for patients who might otherwise face progressive heart failure without warning.
"Routine implementation of this integrated evaluation strategy in the management of HFpEF may facilitate early identification and precision intervention," the authors conclude, "ultimately improving patient outcomes." For the millions of people worldwide living with this form of heart failure, that message carries real weight.